Skip to content
The Policy VaultThe Policy Vault

tolvaptan (generic of Jynarque)Medical Mutual

autosomal dominant polycystic kidney disease (ADPKD) - at risk of rapidly progressing disease

Initial criteria

  • Medication requested is being used to slow kidney function decline
  • Patient age ≥ 18 years
  • Liver function laboratory values (ALT, AST, bilirubin) have been reviewed and are appropriate before initiation
  • Requested drug is prescribed by or under consultation with a nephrologist

Reauthorization criteria

  • Medication requested is being used to slow kidney function decline
  • Requested drug is prescribed by or under consultation with a nephrologist
  • Patient’s kidney function (total kidney volume, albuminuria, onset or progression of hypertension, eGFR, etc.) decline has slowed and/or kidney pain has improved since treatment
  • Provider is monitoring liver function monthly for the first 18 months of treatment, then every 3 months

Approval duration

initial 90 days; reauth 1 year